A phase 1 first-in-human study evaluating safety, pharmacokinetics, and efficacy of ABBV-291, a CD79b-targeting antibody-drug conjugate, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

A post on inventcures.github.io, published 30 September 2026, has not been cited by any blog yet (corpus.blog, measured 14 October 2026).

A record is what was published and who pointed at it. The text of the post is not shown here: read it at the source, or at its Wayback capture.